- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Another Death Reported in Juno's CAR-T Trial in Patients With ALL
Within 4 months of the last reported incident, Juno Therapeutics has again halted the phase 2 “Rocket” trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
It happened again. Within 4 months of the last reported incident, Juno Therapeutics has again halted the phase 2 “Rocket” trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
In a call with investors and in a statement, the company reported that 1 patient on the trial died earlier in the week as a result of cerebral edema, while another, facing similar symptoms, is not expected to recover.
Juno, a pioneer in developing the chimeric antigen receptor T (CAR-T) cell therapy, had to halt the Rocket trial in July this year following the death of 3 patients who were enrolled in the JCAR015 trial, which used fludarabine/cyclophosphamide during the preconditioning step. Mark Gilbert, MD, senior vice president and chief medical officer at Juno, had said during a subsequent conference call that the company would propose removing fludarabine from the procedure.
Following a meeting with the FDA, the trial was restarted.
During today’s call, Hans Bishop, CEO of Juno, said, “These are obviously difficult times for us. Adult ALL is proving to be a difficult disease, but we really are not ready to give up on it.”
While the company will be in discussions with the FDA on next best steps, it plans to continue work on its other CD19-directed CAR-T cell products.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
